Join to View Full Profile
3719 Dauphin Street5TH floorMobile, AL 36608
Phone+1 251-625-6896
Fax+1 251-625-6897
Dr. Meshad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1978 - 1980
USA HealthResidency, Internal Medicine, 1975 - 1978
Letterman Army Medical CenterInternship, Transitional Year, 1972 - 1973
University of Alabama School of MedicineClass of 1972
Certifications & Licensure
AL State Medical License 1975 - 2025
MS State Medical License 2009 - 2016
FL State Medical License 2007 - 2011
NC State Medical License 1973 - 1976
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- RTA 408 Capsules in Patients With Melanoma - REVEAL Start of enrollment: 2014 Oct 31
- Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Publications & Presentations
PubMed
- Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.Elizabeth Koselke, Lisa C Kaspin-Powell, Shannon Hough, Joshua Howell, Nicholas J Robert
Journal of the Advanced Practitioner in Oncology. 2024-07-21 - 5 citationsPaclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.Brenda P. Nicholson, David M. Paul, Kenneth R. Hande, Yu Shyr, Michael Meshad
Clinical Breast Cancer. 2000-07-01 - 16 citationsOral Ondansetron 8 mg Twice Daily is as Effective as 8 mg Three Times Daily in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemo...Thomas M. Beck, Martin York, A Y Chang, Rudolph M. Navari, Walter H. Harvey
Cancer Investigation. 1997-01-01
Press Mentions
- FIGHTING TO WIN: A 28-Year-Old’s Journey Through Colon CancerOctober 20th, 2020
Southern Cancer Center Is Global Leader in Kidney Cancer Clinical TrialSeptember 19th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
